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Abstract
Objective Lung cancer is a major cause of cancer-related
deaths and thus represents a global health problem.
According to World Health Organization (WHO) esti-
mates, approximately 1.37 million people die each year
from lung cancer. Different therapeutic approaches as well
as several treatment options exist. To date decisions on
which therapies to use have largely been made by clinical
experts. Comparative preference studies show that under-
lying weighting of treatment goals by experts is not nec-
essarily congruent with the preferences of affected patients.
Aim and methods The aim of this empirical study was to
ascertain patient preferences in relation to treatment of non-
small-cell lung cancer (NSCLC). After identification of
patient-relevant treatment attributes via literature review
and qualitative interviews(ten) a discrete-choice experiment
including seven patient-relevant attributes was conducted
using a fractional factorial NGene-design. Statistical data
analysis was performed using latent class models.
Results The qualitative part of this study identified out-
come measures related to efficacy, side effects and mode of
administration. A total of 211 NSCLC patients (N = 211)
participated in the computer-assisted personal interview. A
clear preference for an increase in ‘‘progression-free sur-
vival’’ (coef.: 1.087) and a reduction of ‘‘tumor-associated
symptoms’’(cough, shortness of breath and pain); coef.:
1.090) was demonstrated, followed by the reduction of side
effects: ‘‘nausea and vomiting’’ (coef.: 0.605); ‘‘rash’’
(coef.: 0.432); ‘‘diarrhea’’ (coef.: 0.427); and, ‘‘tiredness
and fatigue’’ (coef.: 0.423). The ‘‘mode of administration’’
was less important for participants (coef.: 0.141).
Conclusion Preference measurement showed ‘‘progres-
sion-free survival’’ and ‘‘tumor-associated symptoms’’ had
a significant influence on the treatment decision. Subgroup
analysis revealed that the importance of ‘‘progression-free
survival’’ increases with increased therapy experience.
Based on the presented results therapies can be designed,
assessed and chosen on the basis of patient-oriented find-
ings. As such, more effective and efficient care of patients
can be achieved and benefits increased.
Keywords Discrete-choice experiment  Non-small-cell
lung cancer  Patient preferences  Patient-relevant
treatment attributes
JEL Classification I10  I15  D700
Introduction: non-small-cell lung cancer
Decision problem: evaluation of different NSCLC
therapy options
With the request for greater involvement and participation
on the part of patients and the general societal shift toward
greater self-responsibility, self-determination and auton-
omy the role of the patient is changing [1]. Objective and
clinically-characterized needs assessments and asssociated
decisions should be supplemented by patient perspectives.
The question of optimal treatment for non-small-cell
lung cancer (NSCLC) is currently being examined
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primarily from the experts’ perspective. Decisions about
appraisal, utility and ultimately compensation of health
technologies are made on the basis of these expert judg-
ments grounded on evidence of clinical efficacy obtained in
(randomized) clinical trials. The question of which decision
criteria are important from the perspective of NSCLC
patients and how they are weighted against each other has
not been taken into consideration to date. As different
preference studies have shown, the judgments of experts do
not correlate with the subjective preferences of patient in
some cases [2, 3]. The patients’ criteria are not necessarily
congruent with the endpoints set by experts [4, 5]. In
addition, each endpoint should not necessarily be consid-
ered to carry the same weight in decision-making. Finally,
subgroup differences in terms of preferences between dif-
ferent patient populations can also occur [6].
Research question: identification and weighting
of the decision criteria
As hardly any data are available to date about patient
preferences regarding treatment of NSCLC in Germany,
identification and weighting of patient-relevant outcomes
for decision-making is necessary. Consideration of patient
preferences should improve decisions about utilization of
health technologies in the short term (preference based
treatment alternatives lead to higher compliance and
adherence), strengthen patient orientation in the medium
term (patient-centered treatment alternatives and commu-
nication enhance patient understanding) and improve
clinical effects in terms of morbidity and mortality in the
long term (higher compliance and adherence will lead to
better treatment outcomes). Information on patient prefer-
ences should be available to all stakeholders.
Against this background the following questions are to
be answered in context of an empirical study with German
participants:
• Identification: What are the key decision criteria for the
selection of an optimal NSCLC therapy from the
patients’ perspective?
• Weighting: How do patients weight these different
decision criteria when selecting the optimal NSCLC
therapy?
• Subgroup: Are there differences in weighting of the
relevant decision criteria for different groups of
patients?
We hypothesized that the prolongation of ‘‘progression-
free survival’’ is of highest value for patients. In addition,
we wanted to test if the mode of administration contributed
to overall patient benefit (was significant in the decision
model). Discrete-choice experiments (DCEs) are a com-
monly used method of revealing patient preferences
proposed by the German Health Technology Assessment
(HTA) Agency [Institute for Quality and Efficiency in
Health Care (IQWiG)] [7]. Therefore, this method was seen
as appropriate for answering the research question.
Objective: scientific evidence of patients’ perspectives
The aim of this empirical study was to document patient
preference regarding drug treatment of NSCLC. A DCE
was used to rank patient-relevant treatment characteristics
at the end of the investigation. In addition, results of this
survey can provide a basis for a patient-oriented evaluation
of treatment options for NSCLC and assess the patients’
perspective on the basis of scientific evidence. Against the
backdrop of increasing integration of patients in treatment
decisions insight into patient preferences gained from this
analysis could also be used in the context of shared deci-
sion-making (to help professionals better understand the
patients’ perspective) and could also be taken into account
in (participative) decision-making about future treatment
strategies [8].
Analysis of patient preference will enable patient benefit
to be analysed together with, and in addition to, clinical
effectiveness. Thus, preference data can create a new
source of information (evidence). In this way the added
value of innovative treatment options can be comple-
mented by the patient-perceived benefit based on clinical
trial data [9]. In summary, the objective of the study is to
expand scientific knowledge in the field of NSCLC treat-
ment by adding the patients’ perspective in the form of
preference data.
Decision-making context: burden of disease
and treatment alternatives
Burden of disease: prevalence and incidence
Lung cancer is a major cause of cancer-related deaths and
thus represents a global health problem. Lung cancer is the
most common form of cancer that occurs at an above-
average frequency, especially in the developed countries of
America and Europe. National geographic differences also
exist with regard to prevalence. In larger cities and
industrial regions the probability of developing NSCLC is
usually higher [10].
According to WHO estimates, approx. 1.37 million
people die each year from lung cancer [11]. With over
43,000 deaths, malignant neoplasm of the bronchus and
lung (ICD-10 Pos. Nr. C-34) is the fourth leading cause of
death in Germany [12]. The 5-year survival rate of patients
with lung carcinoma in North America and the European
countries ranges between 5.5 and 15.7 % [10]. Lung cancer
658 A. C. Mu¨hlbacher, S. Bethge
123
is phenotypically divided into non-small-cell lung
(NSCLC) and small-cell lung carcinoma (SCLC). 80–85 %
of lung cancer patients suffer from NSCLC [13].
Smoking has been identified as the main risk factor for
lung cancer, with the duration of smoking being the most
important factor [14]. Passive smoking also increases the
risk. Studies have shown that there are biological differ-
ences in the lung cancer of smokers and non-smokers [15].
Thus, patients who have what are known as adenocarci-
nomas are predominantly non-smokers [16]. Moreover,
epidermal growth factor receptor (EGFR) mutations are
more common in tumors of non-smokers [17, 18]. The
main symptoms of NSCLC are cough, shortness of breath,
weight loss and chest pain. In addition, patients with
NSCLC appear to be more likely to suffer from chronic
obstructive pulmonary disease (COPD) [19].
Treatment (alternatives)
Treatment of NSCLC aims to delay progression of the
tumor cells as long as possible, to increase survival time as
much as possible, to reduce tumor-related symptoms and
ultimately to maintain the patients’ quality of life or even
improve it [10, 20–22]. The best treatment decision is
always one that involves weighing expected benefits
against possible side effects [23–27]. Potential treatment
options are influenced by the stage of disease and factors
such as socio-demographic status, co-morbidities and car-
diopulmonary function [19, 28].
Treatment of NSCLC is based on tumor staging [Clas-
sification of Malignant Tumours (TNM classification)] and
the current condition of the patient. In stages IA to IIB the
primary objective is generally surgical tumor resection
with a curative aim. In advanced stages chemotherapy and
targeted therapies (e.g., tyrosine kinase inhibitors) for
patients with certain mutations and radiotherapy are
applied [22, 29, 30].
Owing to the severity of the disease in stage IIIB and IV
and the associated limited average remaining life expec-
tancy of 8–12 months fast and reliable access to care
(including rehabilitation) should be ensured in addition to
ongoing medical treatment. Current treatment guidelines
recommend first-line cisplatin combination chemotherapy
or tyrosine kinase inhibitors for prolongation of progres-
sion-free survival times, disease control and improvement
in quality of life. Treatments used have to be determined
individually depending on the patient’s general condition,
age and any existing comorbidities. Careful monitoring of
quality of life and the success of therapy has to be ensured
during treatment [20, 21]. Continuing therapy (e.g., sec-
ond-line chemotherapy, surgical removal of the tumor or
metastasis, radiotherapy) are to be determined depending
on the response to first-line therapy, as well as on the
general condition of the patient and the degree of metas-
tasis [10].
Methods and study design: elicitation of patient
preferences
Discrete-choice experiments
The Discrete-Choice Method is a choice-based version of a
conjoint analysis that was made possible by the theoretical
work of Lancaster [31] and McFadden [32]. Instead of
ranking or rating different therapeutic features, as is done
in traditional importance elicitation formats and conjoint
analyses, DCEs perform a pairwise comparison of hypo-
thetical alternatives (i.e., differently configured therapy
options) and ask the participants to choose between them
[33].
Thus respondents are forced to make trade-offs between
attributes and their levels. The method offers practical
advantages such as closeness to reality as trade-off deci-
sions are part of everyday life. Implementation of pairwise
comparisons considerably reduced the degree of com-
plexity of the tasks for the participants [34–36]. Therefore,
DCEs are increasingly used in health economics and health
service research [37, 38].
Multiple steps are involved in the structure and design of
a DCE and its evaluation. Several checklists are available




Attributes and levels At the beginning literature research
on the indication of NSCLC was conducted (PubMed,
Medline, and Cochrane Library) to document the available
state-of-the-art treatment options. Additionally, the method
of concentric circles was used to complement the relevant
literature [40]. The aim of the search was to identify
potential properties and characteristics of NSCLC treat-
ments in general and from the patients’ perspective.
Prior to the main survey a preliminary qualitative study
was conducted. In N = 10, qualitative semi-structured
interviews with NSCLC patients (N = 6), care givers
(N = 3), and other cancer patients (N = 1) were conducted
and the treatment characteristics extracted from the litera-
ture were tested. Previously identified therapeutic features
were confirmed and their relevance to the patients was
assessed. Furthermore, patients could name additional as
yet unidentified treatment attributes that would be patient-
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relevant. This allowed the subjective views of the patients
surveyed to be reflected. Moreover, the interviews were
used to evaluate the clarity of the questionnaire, the quality
of the scales used and the understandability of the attri-
butes, levels and trade-offs included. In parallel, the quality
of the instrument was optimized [41].
The final framework of the attributes used, the charac-
teristics with explanations and associated icons are dis-
played in the following graph (Fig. 1). All level
characteristics were based on realistic studies and con-
firmed by quotations from randomized controlled trials.
These levels were used in the main study to create an
optimal experimental design and the patient-friendly
introductory texts.
As part of the literature review and interviews the
‘‘realistic range of levels’’ was confirmed so that this
analogy could be used to establish the DCE. Description of
the attribute levels was created in the style of the classifi-
cation scheme by the US Department of Health and Human
Services and the Office of Human Research Protection of
the FDA [42]. Furthermore, a detailed patient-friendly
introduction to each single attribute and related level was
included in the survey. The attribute ‘‘progression-free
survival’’ in particular was introduced to avoid any free
interpretations. The participants were informed that neither
overall survival nor quality of life is affected by progres-
sion-free survival within the study context.
Data collection plan, sample size, stratification and
recruitment The survey was conducted from May to June
2013 with computer-assisted personal interviews. Recruit-
ment of patients for the survey was performed by an
external research institute. Patients diagnosed with NSCLC
stage IV who had been treated within the last 2 years and
who were older than 18 years were included in the survey.
Patients who did not meet all the criteria were excluded as
ineligible (disqualified) as were all patients who did not
complete the questionnaire (incomplete).
Ethical considerations The study was a social science
survey and did not contain personal data (completely
anonymous survey), information on surgeries (tests,
experiments, and medication), biomedical research or
additional data, as is the case in many epidemiological



















(1 time in 24 
h)
Moderate




times in 24 h)
Diarrhea
Mild
(1-4 times per 
day)
Moderate

































Mode of administration Tablet - Infusion
Attribute Level 1 Level 2 Level 3
Fig. 1 Overview of the decision model with visualizations. ADL activities of daily living
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investigations. Therefore, an ethics committee vote was not
necessary. All respondents were informed about the study
and its potential risks and benefits prior to participation. All
respondents signed an informed consent form. They par-
ticipated voluntarily and could end their participation at
any time. All documents used in the study went through an
internal approval process by the sponsor of the study.
Data collection: instrument, elicitation technique, tasks
and experimental design
The final decision model was established based on the
qualitative pilot study. Seven patient-relevant characteris-
tics each described by two or three levels were extracted
and included in the main survey (Fig. 1). Overall, the final
questionnaire consisted of five sections. The first part
included socio-demographic questions, such as age, gen-
der, weight, height, marital status, occupation and educa-
tion. This socio-demographic data may be used for
subgroup analyses. The second part of the questionnaire
included questions about current state of health and pre-
vious treatment. The third part included information about
the attributes of the NSCLC drug therapy and realistic
representations of their levels. The fourth section contained
a constant sum question used for personal assessment of
the treatment.
The fifth part contained the 12 choice sets of the DCE.
The subjects indicated which therapy alternative of the two
presented they would choose in each case (trade-off rela-
tionships) (Fig. 2). No opt-out possibility was given. To
simplify the choice for the participants each level of each
attribute was displayed together with a visual aid.
Experimental designs To construct the DCE choice sets
an experimental design (6 9 3; 1 9 2 Design) was created
using NGene software. The selected design consisted of 24
choice sets that were divided into two blocks of 12 choices
so that each patient only had to make 12 decisions. The
design resulted in an efficiency of D-error = 0.072242 and
an A-error of 0.078126. With respect to severity of the
illness and the reduced concentration capabilities of stage 4
NSCLC patients it was necessary to ease the choice tasks
as much as possible. To simplify the choices the moderate
types were modelled so that they were systematically
overlapping, as overlap provides a way to simplify choice
questions by reducing the number of attribute differences
respondents have to evaluate [43]. The experimental design
was therefore robust against potential recruitment problems
and was easier to understand for seriously ill participants in
the survey. Owing to the underlying dichotomous design, a
subgroup analysis was possible when the planned sample
size had been achieved.
Fig. 2 Example choice set of
the discrete-choice experiment
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According to the Orme calculation, the minimum sam-
ple size was N = 126 participants. As this calculation is
currently debated in terms of being the lowest limit and
given the severity of the disease, the restrictive access
criteria, and the limited recruitment options, a sample size
of N = 200 subjects was envisaged to guarantee a statis-
tically robust estimate [44].
Data analysis: data structure, statistical model,
subgroup analysis, and interpretation
To estimate the relative importance of each treatment attri-
bute latent class models were used with discrete or contin-
uous random vectors and coefficients calculated using
GLLAMM 2.3.20 in Stata 11.2 for Mac [45, 46]. The data set
was further structured as follows: 211 subjects 9 12 choice
tasks per subject (2,532 choice sets) 9 2 alternatives per
choice set (5,064 alternatives). Alternatives were assigned 0
if the respondent did not choose this alternative and 1 if he or
she chose the alternative in the choice set.
Effects coding was used (-1, 0, 1) for all seven attributes
associated with two or three levels of the attributes within
the model calculation. The worst level (i.e., highest prob-
ability of a negative impact on the decision) in each case
was determined as the reference category and assigned -1.
All GLLAMM models were fitted using a multi-nominal
logit link function and binomial distribution for the binary
response. First of all, a main effects model (one-class
model) that assumes that the population of respondents is
homogeneous in the weighting (expected utility) was cal-
culated for each attribute. In addition, ‘‘multi-group mod-
els’’ (2 class, 3 class, and 4 class GLLAMM models) were
calculated, by specifying latent class models using a dis-
crete random coefficients vector. Identification of groups
made it possible to identify patterns related to these groups
using structural variables. The group models thus provided
information about the likelihood of possible subjects fall-
ing into a specific group on the basis of the respective
structural variables. The model estimates in terms of
structural parameters within the latent class model were
subsequently calculated, which reflects the strength of
influence of the individual structure parameters in each
class. ‘‘Likelihood ratio tests’’, Akaike information crite-
rion (AIC), and Bayesian information criterion (BIC) were
used to check the accuracy of the model, to determine the
most appropriate model and to test for parameters that
might improve the model fit.
Results are reported as estimated parameters of the main-
effects model (1 class) and of a latent-class model with three
classes. While we did not include a cost attribute, prefer-
ence estimates were rescaled into progression-free survival
equivalents analogous to willingness to pay (WTP) using a
nonmonetary numeraire. For interpretation of ‘‘progression-
free survival’’ as ‘‘currency,’’ it was possible to evaluate the
marginal rate of substitution in relation to the other risk
attributes. The information can be derived via how much
time a respondent was willing to ‘‘give up’’ for an
improvement from a severe side effect to a mild one.. Or
vice versa, how much of a side effect a respondent was
willing to accept to get one more (progression-free) month.
Results
Respondent characteristics: socio-demographic data
In the total sample 64.5 % of participants were male and
the mean age was 58.9 years (min 29, max 82, SD 8.44).
68.2 % of the subjects stated that they were married. Par-
ticipant education followed a normal distribution with 52.1
% cumulative disclosures of an intermediate high-school
diploma or technical college qualification.
40.3 % of respondents were retired with 32.7 % currently
incapable of working. 11.8 % of the respondents were still in
part- or full-time jobs. 6.6 % of the respondent had received
their NSCLC diagnosis less than 6 months ago, 13.8 %
6 months to 1 year ago, 36.0 % 1–2 years ago and 34.1 % of
people had been diagnosed 2–5 years ago. 9.0 % reported
that they had been diagnosed more than 5 years ago.
14.7 % of respondents said that they rated their current
health as ‘‘good’’ or ‘‘very good’’. 52.6 % rated their health
as ‘‘satisfactory’’ and 32.7 % indicated that their current
health was ‘‘less good’’ or ‘‘poor’’ (Table 1).
Results of the main effects model
A total of N = 211 complete records were transferred to
the database and included in the final quantitative data
analysis.
The basic model displayed a significant coefficient for
all attributes included. This shows that, independent of the
placement, all attributes were relevant to the patients’
decision (Table 2). It can be deduced therefore that all
attributes included in the decision model have an impact on
the therapeutic decisions made by NSCLC patients.
The main effects model (linear model), which assumed a
homogeneous distribution within the population of partici-
pants, showed that ‘‘progression-free survival’’ (Coef.: 1.087;
OR.: 2.966) and ‘‘tumor-associated symptoms’’ (cough,
shortness of breath, and pain) (Coef.: 1.090; OR.: 2.975) are in
first place in the preference weights (no significant difference).
Because of the coding used in the statistical model, the highest
coefficient shows the highest influence in the decision model.
Specifically, for an attribute to improve from the worst to the
best level (manifestation), the attribute with the highest coef-
ficient will also act as the strongest stimulus to the decision.
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The third position is occupied by ‘‘nausea and vomiting’’
(Coef.: 0.605; OR.: 1.832), followed by ‘‘rash’’ (Coef. 0.432;
OR 1.540), ‘‘diarrhea’’ (Coef. 0.427; OR 1.533) and ‘‘tiredness
and fatigue’’ (Coef. 0.423; OR 1.527); these attributes are also
very close to each other. The group of side effects can be
considered together to facilitate later interpretation.
The ‘‘mode of administration’’ was estimated to be in
the last position (Coef.: 0.141; OR.: 1.152). It exerts by far
the least impact on the therapy decision in comparison to
other patient-relevant attributes.
Results of the latent class model and analysis
of subgroups
Preference differences depending on structural variables
To identify possible subgroup differences starting from the
initial main effects model a two-class model and, subse-
quently, a three-class model were generated. Based on
Table 1 Socio-demographic structure of patient sample (N = 211)







54 years and younger 26.1 55
55–64 years 46.0 97





Divorced or separated 10.4 22
Single 4.3 9
In a relationship, but not married 8.1 17
Education level
No degree 2.4 5
Junior/middle school certificate 16.1 34






Abitur, high school diploma, in Germany:
university entrance qualification
14.1 31
Technical college degree 7.6 16
University degree or higher 7.1 15
Employment status
Employed full-time 3.3 7




Disabled/unable to work 32.7 69
Unemployed 1.4 3
Time of NSCLC diagnosis
Less than 6 months ago 6.6 14
6 Months–1 year ago 13.7 29
1–2 years ago 36.0 29
2–5 years ago 34.1 72
More than 5 years ago 9.0 19
Not sure 0.5 1
Treatment status-current treatmenta





Drug therapy (including chemotherapy) 82.5 174
Other 0.5 1
Table 1 continued









Drug therapy (including chemotherapy) 84.8 179
Other – –
With whom do you live in a household?a
Spouses 77.3 163
One or more adult children (18 years or older) 13.7 29
One or more minor children (under 18 years) 8.5 18
Parents/parent – –
I live alone 19.9 42
Others 1.4 3
Within your treatment how severe did the side effect diarrhea occur?




Not sure 0.9 2
Within your treatment how severe did the side effect fatique occur?




Not sure 8.5 18
a Multiple replies possible
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examination of the model fit using AIC and BIC (both
indicators for the assessment of overall quality of models)
the three-class model could be identified as suitable for
illustration of existing heterogeneity in response behavior
as well as for representing the probable allocation of sub-
jects per group. As the choice-tasks contained systematic
overlap of the middle level based on the experimental
design only the coefficients for the first and third level
could be evaluated. Therefore the linearity assumption
between the levels has to be applied within all estimations.
Seven structural or personal variables were identified to
explain the impact on a subjects’ probability of class
membership. Significant indicators for group differences
were ‘‘previous treatment,’’ ‘‘education: vocational
school,’’ ‘‘one or more adult children (18 years or older),’’
‘‘currently undergoing treatment with radiotherapy,’’
‘‘marital status: widowed and/or divorced,’’ ‘‘high burden
of side effects: diarrhea’’ and ‘‘not sure’’ for the side effect
‘‘fatigue.’’ The three different preference patterns (repre-
sented by the relevant classes) (see Fig. 3) were less
dependent on the socio-demographic factors included in
the questionnaire.
The socio-demographic characteristics ‘‘age’’ and
‘‘gender’’ did not influence the calculated latent class
model. It is concluded that these characteristics have no
influence on preference in the present decision-making
model.
Preference patterns class 1
The preference pattern of class 1 [N = 47 (22.6 %)] is
similar to the linear model for estimation of the main
effects (relative importance). The attributes ‘‘progression-
free survival’’ and ‘‘tumor-associated symptoms’’ are
weighted the highest. The attributes ‘‘diarrhea’’ and ‘‘mode
of administration’’ received a negative coefficient in this
model. This suggests that respondents are ‘‘willing to
accept’’ these attributes in the selection decision in this
class. For the attribute ‘‘tiredness and fatigue’’ no signifi-
cant coefficient was calculated, which would appear to
Table 2 Estimated parameters
of the main-effects model
(1 class)
a Upper bound
b Lower bound, number of level 1
units = 5,064, log
likelihood = -980.06933
Attribute Coeff. Odds ratio SE 95 % confidence interval P value z
UBa LBb
Progression-free survival 1.087 2.966 0.0525 1.1902 0.9846 0.000 20.73
Rash 0.432 1.540 0.0396 0.5094 0.3541 0.000 10.89
Nausea and vomiting 0.605 1.832 0.0481 0.6995 0.5109 0.000 12.58
Diarrhea 0.427 1.533 0.0396 0.5051 0.3498 0.000 10.79
Fatigue (tiredness) 0.423 1.527 0.0380 0.4977 0.3486 0.000 11.13
Tumor-associated symptoms 1.090 2.975 0.0562 1.2005 0.9801 0.000 19.39






































































norm. Coef. Class 1 norm. Coef. Class 2 norm. Coef.  Class 3
Fig. 3 Evaluation of preference
patterns for Class 1, 2 and 3 on
the basis of normalized
parameters. To increase
comparability of the weighting
coefficients, normalization on a
10-point scale was used
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indicate that this attribute had no effect on the decision of
this subpopulation.
Evaluation of structural variables for class 1
Class 1 includes a below-average number of people with
adult children in the household (as opposed to class 3).
Higher preference for infusion (indicated by the negative
sign) might be due to the fact that persons in this class
might prefer to be treated at a hospital and to have direct
access to medical care if needed (as this group has below-
average adult children within the household). An above-
average number of patients with a vocational education can
also be found in class 1. The patients matched in class 1
have all undergone previous treatment and none of the
patients indicated that they ever received ‘‘no treatment and
only regular checks.’’ ‘‘No treatment’’ periods refer to the
interval between two chemotherapies, for example, or
when a decision has been made to stop treatment and to
control the progression of the tumor only. Since this is a
deterministic context this cannot be represented in the
model. Moreover, the significance of this parameter is
rather low.
Preference patterns class 2
The preference pattern of class 2 [N = 85 (40.5 %)] is
comparable with that of class 1 and with the main
effects model in respect to the importance of the
attributes ‘‘progression-free survival’’ and ‘‘tumor-
associated symptoms.’’ One characteristic of the second
class, however, is that the side effect attributes have
increased substantially in importance and the differ-
ences between the outcome attributes and the side
effect attributes are lower than in either the first group
or in comparison with the main effects model.
Evaluation of structural variables for class 2
Class 2 has fewer participants currently in radiotherapy.
On the other hand, there are an above-average number
of patients who state that they are widowed. Also, rel-
atively fewer people are divorced. Furthermore, persons
with the class 2 preference patterns had experienced on
average an increased burden from the side effect
‘‘diarrhea’’ in their therapy. Identical to class 1, class 2
only includes patient with previous treatment. None of
the patients indicated that they received ‘‘no treatment
and only periodic checks.’’
Preference patterns class 3
It is striking that the preference pattern in class 3 [N = 79
(36.9%)] is relatively the same across all seven attributes.
Furthermore, the attributes ‘‘progression-free survival’’ and
Table 3 Estimated parameters of latent-class model
Parameter (standard error)
Attribute Class 1 coef. (SE) Class 2 coef. (SE) Class 3 coef. (SE)
Progression-free survival 4.032 (0.9151)*** 3.608 (0.8595)*** 0.611 (0.0805)***
Rash 0.436 (0.1345)*** 0.737 (0.1967)*** 0.775 (0.0840)***
Nausea and vomiting 0.883 (0.1995)*** 1.603 (0.4336)*** 0.854 (0.0866)***
Diarrhea -0.781 (0.1776)*** 1.585 (0.3491)*** 0.668 (0.0701)***
Fatigue (tiredness) 0.034 (0.3603)* 1.305 (0.3144)*** 0.514 (0.0709)***
Tumor-associated symptoms 2.442 (0.4874)*** 3.574 (0.6994)*** 0.726 (0.0890)***
Mode of administration -1.378 (0.5593)** 0.912 (0.2594)*** 0.142 (0.0556)**
Proportion of patients per class 47 (22.6%) 85 (40.5%) 79 (36.9%)
Constant per class -0.4895 (0.2075) 0.0915 (0.2208) –
Class-membership parameters
No treatment, only checkups (previous treatment) – – ??
Education: vocational school ??
Household: one or more adult children (18 years or older) – ??
Currently in treatment with radiotherapy – ??a
Marital status: widowed and/or divorced ??
High burden of side effects: diarrhea ??
’’Not sure’’ with side effect ‘‘fatigue’’ ??
*** p\ 0.0001, ** p\ 0.001, * p = not sign, - below average number of patients, ? above average number of patients
a This includes only patients who were treated
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‘‘tumor-associated symptoms’’ are not ranked the highest in
class 3, but the difference in the preference weights is
rather low.
Evaluation of structural variables for class 3
The people in class 3 were more likely to live with adult
children. In contrast to class 2 an above-average number of
people in class 3 stated they were currently having radio-
therapy. Also in contrast to class 2, people indicated that
they had experienced fewer episodes of ‘‘diarrhea’’ during
therapy. Persons who have experience with control
sequences in therapy and periods of ‘‘no treatment’’ are
predominantly found in class 3. And finally, all patients in
class 3 have indicated ‘‘not sure (if adverse event was
experienced)’’ in response to the question about fatigue and
tiredness experienced as a side effect.
Verification of model performance using a likelihood ratio
test
In addition to representation of the proportional distribu-
tion within the latent class regression model a likelihood
ratio test was performed. It is possible to determine, based
on the results of the likelihood ratio test for different
quantity of classes, which model parameters improve the
quality of the three-class model. The likelihood ratio test
also takes into account the increase in the degrees of
freedom which can result in the regression model yielding
divergent results. It should also be noted that in this
calculation all covariates were included directly in the
model and thus estimates of the size of classes can be
affected as can the parameter estimates of the attributes.
In other words, by using the likelihood ratio test it was
determined how far the model fit can be improved if the
estimated coefficients are set dependent on a covariate
(based on the estimated coefficients and related SE dis-
played in Table 3). In total three different models were
estimated and compared; the three-class model performed
best.
The parameters in the model specify whether the prob-
ability of class membership is increased or decreased by a
structural feature. If a parameter is positive and significant
this increases the probability of class membership. For
example, if a parameter for class 2 is positive and signifi-
cant this means that a person with this characteristic is
more likely to belong to class 2 than class 3. In reviewing
the model the variables ‘‘currently in treatment with
radiotherapy,’’ ‘‘currently in treatment with medication’’
(including chemotherapy), ‘‘side effect: fatigue’’ (in all
four levels) and ‘‘household type: one or more adult chil-
dren (18 years or older)’’ were identified as predictors for
the improvement of the model quality. The exploratory
nature of this approach should be noted and the fact that in
multiple testing of all structural parameters the risk of
random statistical significance cannot be excluded. This
analysis can thus be understood as a complement to the
latent class model. The probability of class membership in
class 1 or 2 is positively determined by the properties
‘‘current treatment: medical treatment (including chemo-
therapy).‘‘ These were the classes in which ‘‘progression-
free survival’’ and ‘‘tumor-associated symptoms’’ were
considered to be the most relevant. Similarly, there is an
increased probability of the class including people who
experienced the ‘‘side effect: fatigue.’’ Patients who dis-
closed ‘‘side effect fatigue: not sure’’ were more likely to
pertain to class 3 (see also regression model). An increased
class membership for class three is triggered by the prop-
erties ‘‘current treatment in radiotherapy’’ and ‘‘household
type: one or more adult children (18 years or older).’’ This
is in direct concordance to the regression model and is thus
confirmed.
Discussion:
Interpretation of DCE results
Descriptive results
Distribution of the present sample is similar to the sys-
tematic review of Blinman and colleagues [23], which
exclusively determined preference studies on NSCLC
chemotherapy. In concordance, the majority of those
affected were male (65%) and the average age was about
58 years and thus in the second half of life. The current
treatment guidelines mention a median age of 67 years for
German NSCLC patients in stage III and IV while the
present sample is somewhat younger [10].
Consistent with the literature, the majority of the
included subjects were married, in so far as the data
available from other studies allowed for this comparison.
The present study includes by far the highest number of
NSCLC cancer patients. A total of N = 211 NSCLC
patients were included in the present study while compa-
rable studies included a range of 56 to 100 cancer patients
(not all NSCLC) [23, 47]. Owing to the severity of the
indication this constitutes a unique characteristic of the
study.
Relative importance
Similar to results obtained in the US context [47] the
attributes ‘‘progression-free survival’’ and ‘‘tumor-associ-
ated symptoms’’ were identified as the two key patient-
relevant characteristics in the present study. This implies
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that the sole consideration of ‘‘progression-free survival’’
as the foundation for decisions is not sufficient from the
patients’ perspective and multiple criteria are important.
Patient benefit is determined by ’’progression-free sur-
vival‘‘ and ’’tumor-associated symptoms‘‘ in approximately
equal measure. Therefore, both features should be consid-
ered in allocation and treatment decisions. In the present
decision model the patient benefits are determined by
’’progression-free survival‘‘ and tumor-associated symp-
toms as well as side effects. Therefore multi-criteria deci-
sion models should be taken into account in allocation and
treatment decisions.
In contrast to a study from the US, which ranks ‘‘fatigue
and tiredness’’ in first place of all included side effects
[47], the patients in the present study assessed the side
effect ‘‘nausea and vomiting’’ as the most important side
effect in their treatment decisions.
A study by Dubey et al. demonstrated that 73 % of
NSCLC patients report they make treatment decisions on
the basis of potential side effects if an approximately
equal effectiveness is expected [27]. In the present study
and in line with Dubey et al. the side effects were equally
rated as the second most important block in addition to
the effectiveness of treatment and tumor-associated
symptoms. Therefore, side effects have a significant
impact on the treatment decision. Following the main
outcome attributes the possible side effects were weighted
by the patients. ‘‘Nausea and vomiting’’ was rated higher
than ‘‘rash.’’ A possible explanation might be that suf-
ferers are severely affected by ‘‘nausea and vomiting’’ in
their daily life. The patients associate nausea and vomit-
ing with a restriction of their activities of daily living and
possibly with a reduction in their quality of life. A ‘‘rash’’
tends to be connected with the need for medical inter-
vention; ‘‘Rash’’ is treated and corrected and thus might
be perceived as ‘‘less restrictive.’’
The expectation of benefit from all attributes included
show that a high acceptance by patients can be expected for
the use of a drug therapy that provides these properties [4].
The inclusion of patient preferences in therapeutic deci-
sions implies stronger patient focus and can be simulta-
neously valuable for the development of drug therapy in
the indication of NSCLC.
Subgroup effects
Different studies investigated which patient characteristics
(structural variables) could have an influence on the for-
mation of preferences and obtained differing results. One
study showed a dependence on educational status, whereas
another study found no correlation. Also, different relations
were found regarding the age variable. Only the variable
‘‘sex’’ consistently showed no correlation to preferential
results in all studies. This is also in accordance with the
present results [24, 25, 49–51].
Individual effects of the subgroup analysis applied in
this study are in concordance with the results of Blinman
et al. [23]. Similarly, no relevant differences in preference
patterns by socio-demographic characteristics such as age
and sex could be determined.
Marginal rate of substitution and time equivalent
Only a few studies have explored deriving clinically-rele-
vant time-equivalents from DCE data. Following standard
consumer theory the marginal rate of substitution (MRS)
between attributes can be obtained by calculating the ratio
of the partial derivatives of each attribute. This calculation
addresses the question of how many side effects respon-
dents were willing to accept in order to get one more
progression-free month. For one additional month without
tumor progression respondents were willing to accept:
• An increase of 0.359 from mild to severe side effects of
skin (rash).
• An increase of 0.257 from mild to severe nausea and
vomiting.
• An increase of 0.364 from mild to severe diarrhea.
• An increase of 0.367 from mild to severe tiredness/
fatigue.
• An increase of 0.142 from mild to severe tumor related
symptoms.
In the presence of a linear additive (indirect) utility
function compensating estimates can be calculated for a
marginal change from mild to severe for each risk attribute
by dividing the coefficient of the risk attribute by the
coefficient of the time attribute (time without tumor pro-
gression). The time equivalent (TE) is the mean maximum
time a respondent was willing to forego for an improve-
ment in a single risk attribute. For an improvement from
severe to mild in each risk attribute respondents were
willing to forego:
• 2.782 months for an improvement in side effects of
skin (rash).
• 3.896 months for an improvement in nausea and
vomiting.
• 2.750 months for an improvement in diarrhea.
• 2.724 months for an improvement in tiredness/fatigue.
• 7.019 months for an improvement in tumor related
symptoms.
Assignment of different models
To be able to derive implications for the usage within, for
example, an HTA context, the linear model would be
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needed in the first place because it presents a weight for
each attribute. Analysis and explanations of the heteroge-
neity within the latent class model could help shared
decision making by visualising different patient clusters
and different need structures. Clustering of patients indi-
cated within the latent class might help the physician to
identify patient preference and use a patient-centered
treatment. Furthermore, within an HTA context the latent
class model could help to support the approval of a treat-
ment option within specific subgroups.
Limitations of the study
Firstly, recruitment was conducted via a market research
company. This could have influenced the study population
with respect to individual parameters that could not be
examined in total. Access to the market research company
is, however, free to everybody. Analysis of the socio-
demographic data showed a pattern similar to other studies.
New methodological discussions address the issue of
potential rescaling effects within preference estimates. This
would relate to the attribute progression-free survival
equivalents analogous to WTP using a non-monetary
numeraire. During the pretest participants were fully aware
of the progression-free survival time and the fact that it
differed between levels. We estimated the MRS and a TE.
Given the importance of obtaining a valid estimate of the
marginal utility of time, a validity test of sensitivity to
scope should have been included to test the hypothesis that
respondents paid attention to absolute time levels and did
not interpret the time levels simply as ‘‘low,’’ ‘‘medium’’
and ‘‘high.’’ As this was not part of the experimental design
any discussion of this issue can only be addressed as a
demonstration of the need for further research.
It should be mentioned that the patients’ evaluation with
respect to ‘‘rash’’ (even if it does not play a dominant part
in weighting) might change given the fact that an increased
rash may be an indicator of a positive reaction to therapy,
as demonstrated in several studies [48]. Since ‘‘rash’’ in the
present study should be included solely as a side effect this
observation was not relevant.
As other studies have also shown, preferences can
depend on the cultural background of the study samples
and the existing healthcare system as a context factor [23].
When interpreting the study results it is important to
remember that a German study sample was used. Further-
more, it cannot be ignored that interaction might be pres-
ent. Since the experiment was not designed to discern
interactions this would need to be addressed in a future
experiment.
It is further noted that study participants did not make
decisions with their relatives or their physicians, which
could differ depending on the patients and their healthcare
provider setting. Different stakeholders may have different
preferences. As part of an evaluation process it should be
possible to take any perspective into account, i.e., that of
decision makers, ordinary citizens, patients, the insured or
experts. Information about individual views and priorities
is necessary.
Conclusion
Considering the current buzzwords such as ‘‘patient
involvement’’ and ‘‘shared decision-making’’ patient pref-
erences should be understood and analysed and the
objectives of NSCLC patients regarding therapies and
medications should be known.
NSCLC treatment decisions are very complex and
require a fine balance between potential outcomes and
simultaneous potential risks and side effects. Present data
show patients give highest weighting to ‘‘progression-free
survival’’ and ‘‘tumor-associated symptoms.’’ Thus,
reduction of ‘‘tumor-associated symptoms’’ and the
increase in ‘‘progression-free survival’’ are of crucial
importance for NSCLC patients in the context of possible
therapies. Potential side effects and the associated impair-
ments are traded against them.
This study showed DCEs are appropriate for identifying
and weighting patient-relevant characteristics of NSCLC
treatment options in terms of possible treatment alterna-
tives. The DCE features a high degree of realism and is
easy for the patient to handle.
In this study the essential decision criteria for an optimal
drug therapy for the treatment of NSCLC from the NSCLC
patients’ view were obtained by using a comprehensive
theoretical as well as application-oriented overview of the
use of a DCE. Also, patient-relevant outcome measures and
the weight attached to different treatment properties and
their characteristics by NSCLC patients were determined.
Thus, this study revealed how patients evaluate different
aspects of drug therapy. These data therefore can be used to
add patient evidence to clinical evidence when making
treatment or HTA decisions and therefore to extend
available knowledge. Incorporating patient perspective into
treatment and reimbursement decisions can optimize allo-
cation of scarce resources. In the context of multi-criteria
decision-making, a cardinal scale ranking weighting coef-
ficients can be used for the aggregation of patient benefit to
assess overall benefit compared to the comparator drug.
Despite the above-mentioned limitations, the results are
of high importance. Thus, the DCE provides a practical
approach that can help improve communication between
patients and providers. In addition, the method used in
DCEs has the potential to support clinical and allocative
decision-making and to improve the quality of patient care
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in the long term. Thus, therapies can be designed, assessed
and chosen on the basis of patient-oriented findings. As
such, a more effective and efficient care of patients can be
achieved and benefits increased [4].
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